211 related articles for article (PubMed ID: 10491363)
21. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis of alveolitis in interstitial lung manifestation in connective tissue diseases: importance of late inspiratory crackles, 67 gallium scan and bronchoalveolar lavage.
Witt C; Dörner T; Hiepe F; Borges AC; Fietze I; Baumann G
Lupus; 1996 Dec; 5(6):606-12. PubMed ID: 9116705
[TBL] [Abstract][Full Text] [Related]
23. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
Kowal-Bielecka O; Kowal K; Rojewska J; Bodzenta-Lukaszyk A; Siergiejko Z; Sierakowska M; Sierakowski S
Ann Rheum Dis; 2005 Sep; 64(9):1343-6. PubMed ID: 16100339
[TBL] [Abstract][Full Text] [Related]
25. Preliminary report: the origin of lavage neutrophils in fibrosing alveolitis associated with systemic sclerosis.
Reich JM
Sarcoidosis Vasc Diffuse Lung Dis; 1997 Sep; 14(2):189-90. PubMed ID: 9306513
[No Abstract] [Full Text] [Related]
26. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.
Bouros D; Wells AU; Nicholson AG; Colby TV; Polychronopoulos V; Pantelidis P; Haslam PL; Vassilakis DA; Black CM; du Bois RM
Am J Respir Crit Care Med; 2002 Jun; 165(12):1581-6. PubMed ID: 12070056
[TBL] [Abstract][Full Text] [Related]
27. [Bronchoalveolar lavage in fibrosing alveolitis--a parameter for evaluating activity and prognosis?].
de Wall N; Endres P
Pneumologie; 1991 Oct; 45(10):785-9. PubMed ID: 1758846
[TBL] [Abstract][Full Text] [Related]
28. BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis.
Scheja A; Larsen K; Todorova L; Tufvesson E; Wildt M; Akesson A; Hansson L; Ellis S; Westergren Thorsson G
Eur Respir J; 2007 Mar; 29(3):446-52. PubMed ID: 17107986
[TBL] [Abstract][Full Text] [Related]
29. [Cytological examination of bronchoalveolar lavage fluid and its clinical significance in patients with diffuse interstitial lung diseases].
Li ZH; Hou XM; Li BJ
Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):2-4, 59. PubMed ID: 2401165
[TBL] [Abstract][Full Text] [Related]
30. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease.
De Santis M; Bosello SL; Peluso G; Pinnelli M; Alivernini S; Zizzo G; Bocci M; Capacci A; La Torre G; Mannocci A; Pagliari G; Varone F; Pistelli R; Danza FM; Ferraccioli G
Clin Respir J; 2012 Jan; 6(1):9-17. PubMed ID: 21801327
[TBL] [Abstract][Full Text] [Related]
31. Exhaled nitric oxide is increased in active fibrosing alveolitis.
Paredi P; Kharitonov SA; Loukides S; Pantelidis P; du Bois RM; Barnes PJ
Chest; 1999 May; 115(5):1352-6. PubMed ID: 10334152
[TBL] [Abstract][Full Text] [Related]
32. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.
Clements PJ; Roth MD; Elashoff R; Tashkin DP; Goldin J; Silver RM; Sterz M; Seibold JR; Schraufnagel D; Simms RW; Bolster M; Wise RA; Steen V; Mayes MD; Connelly K; Metersky M; Furst DE;
Ann Rheum Dis; 2007 Dec; 66(12):1641-7. PubMed ID: 17485423
[TBL] [Abstract][Full Text] [Related]
33. Type III and type I procollagen markers in fibrosing alveolitis.
Lammi L; Ryhänen L; Lakari E; Risteli J; Pääkkö P; Kahlos K; Lähde S; Kinnula V
Am J Respir Crit Care Med; 1999 Mar; 159(3):818-23. PubMed ID: 10051256
[TBL] [Abstract][Full Text] [Related]
34. Pathogenetic and clinical significance of fibroblast activation in scleroderma lung disease.
Behr J; Adelmann-Grill BC; Hein R; Beinert T; Schwaiblmair M; Krombach F; Fruhmann G
Respiration; 1995; 62(4):209-16. PubMed ID: 8578017
[TBL] [Abstract][Full Text] [Related]
35. [Correlation between bronchoalveolar lavage and lung function in patients with systemic sclerosis and rheumatoid arthritis].
Pejcić T; Stanković I; Rancić M; Djordjević I; Ristić L; Vojinović J
Srp Arh Celok Lek; 2005 Dec; 133 Suppl 2():129-33. PubMed ID: 16535997
[TBL] [Abstract][Full Text] [Related]
36. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment.
Sahhar J; Littlejohn G; Conron M
Intern Med J; 2004 Nov; 34(11):626-38. PubMed ID: 15546457
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
[TBL] [Abstract][Full Text] [Related]
38. Bronchoalveolar lavage fluid (BALF) analysis in interstitial lung diseases--a 7-year experience.
Sharma SK; Pande JN; Verma K; Guleria JS
Indian J Chest Dis Allied Sci; 1989; 31(3):187-96. PubMed ID: 2638654
[TBL] [Abstract][Full Text] [Related]
39. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison.
Wells AU; Hansell DM; Rubens MB; Cailes JB; Black CM; du Bois RM
Am J Respir Crit Care Med; 1997 May; 155(5):1657-64. PubMed ID: 9154872
[TBL] [Abstract][Full Text] [Related]
40. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
